Tags

Type your tag names separated by a space and hit enter

Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Cancer. 2007 Sep 01; 110(5):1003-9.C

Abstract

BACKGROUND

Given the limited data regarding the impact of obesity on treatment outcomes after external beam radiation therapy (EBRT) for the definitive treatment of prostate cancer, the authors sought to evaluate the effect of obesity as measured by body mass index (BMI) on biochemical disease recurrence (BCR) using the most current 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition (prostate-specific antigen [PSA] nadir + 2 ng/mL).

METHODS

A retrospective cohort study identified men who underwent primary EBRT for localized prostate cancer between 1989 and 2003 using the Center for Prostate Disease Research (CPDR) Multi-center National Database. BMI was calculated (in kg/m(2)) and the data were analyzed. Univariate and multivariate Cox proportional hazards regression analyses were used to determine whether BMI significantly predicted BCR.

RESULTS

Of the 1868 eligible patients, 399 (21%) were obese. The median age of the patients and pretreatment PSA level were 70.2 years and 8.2 ng/mL, respectively. Of 1320 patients for whom data were available with which to calculate PSA recurrence (PSA nadir + 2 ng/mL), a total of 554 men (42.0%) experienced BCR. On univariate analysis, BMI was found to be an independent predictor of PSA recurrence (P = .02), as was race, pretreatment PSA level, EBRT dose, clinical T classification, Gleason score, PSA nadir, and the use of androgen-deprivation therapy (ADT). On multivariate analysis, BMI remained a significant predictor of BCR (P = .008).

CONCLUSIONS

To the authors' knowledge, this is the first study to report the association between obesity and BCR after EBRT for localized prostate cancer as measured by the updated 2006 RTOG-ASTRO definition. A higher BMI is associated with greater odds of BCR after undergoing definitive EBRT.

Authors+Show Affiliations

Department of Urology, Naval Medical Center, San Diego, CA 92134, USA. spstroup@nmcsd.med.navy.milNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

17614338

Citation

Stroup, Sean P., et al. "Effect of Obesity On Prostate-specific Antigen Recurrence After Radiation Therapy for Localized Prostate Cancer as Measured By the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix Consensus Definition." Cancer, vol. 110, no. 5, 2007, pp. 1003-9.
Stroup SP, Cullen J, Auge BK, et al. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. Cancer. 2007;110(5):1003-9.
Stroup, S. P., Cullen, J., Auge, B. K., L'Esperance, J. O., & Kang, S. K. (2007). Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. Cancer, 110(5), 1003-9.
Stroup SP, et al. Effect of Obesity On Prostate-specific Antigen Recurrence After Radiation Therapy for Localized Prostate Cancer as Measured By the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix Consensus Definition. Cancer. 2007 Sep 1;110(5):1003-9. PubMed PMID: 17614338.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. AU - Stroup,Sean P, AU - Cullen,Jennifer, AU - Auge,Brian K, AU - L'Esperance,James O, AU - Kang,Song K, PY - 2007/7/7/pubmed PY - 2007/10/18/medline PY - 2007/7/7/entrez SP - 1003 EP - 9 JF - Cancer JO - Cancer VL - 110 IS - 5 N2 - BACKGROUND: Given the limited data regarding the impact of obesity on treatment outcomes after external beam radiation therapy (EBRT) for the definitive treatment of prostate cancer, the authors sought to evaluate the effect of obesity as measured by body mass index (BMI) on biochemical disease recurrence (BCR) using the most current 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition (prostate-specific antigen [PSA] nadir + 2 ng/mL). METHODS: A retrospective cohort study identified men who underwent primary EBRT for localized prostate cancer between 1989 and 2003 using the Center for Prostate Disease Research (CPDR) Multi-center National Database. BMI was calculated (in kg/m(2)) and the data were analyzed. Univariate and multivariate Cox proportional hazards regression analyses were used to determine whether BMI significantly predicted BCR. RESULTS: Of the 1868 eligible patients, 399 (21%) were obese. The median age of the patients and pretreatment PSA level were 70.2 years and 8.2 ng/mL, respectively. Of 1320 patients for whom data were available with which to calculate PSA recurrence (PSA nadir + 2 ng/mL), a total of 554 men (42.0%) experienced BCR. On univariate analysis, BMI was found to be an independent predictor of PSA recurrence (P = .02), as was race, pretreatment PSA level, EBRT dose, clinical T classification, Gleason score, PSA nadir, and the use of androgen-deprivation therapy (ADT). On multivariate analysis, BMI remained a significant predictor of BCR (P = .008). CONCLUSIONS: To the authors' knowledge, this is the first study to report the association between obesity and BCR after EBRT for localized prostate cancer as measured by the updated 2006 RTOG-ASTRO definition. A higher BMI is associated with greater odds of BCR after undergoing definitive EBRT. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/17614338/Effect_of_obesity_on_prostate_specific_antigen_recurrence_after_radiation_therapy_for_localized_prostate_cancer_as_measured_by_the_2006_Radiation_Therapy_Oncology_Group_American_Society_for_Therapeutic_Radiation_and_Oncology__RTOG_ASTRO__Phoenix_consensus_definition_ L2 - https://doi.org/10.1002/cncr.22873 DB - PRIME DP - Unbound Medicine ER -